Skip to main content

ChEMBL Group Research Retreat 2009

I have provisionally planned the ChEMBL group retreat for 2009. It will be in Crieff, Scotland, and will be in late September. The format will allow detailed discussion and brainstorming of ideas for the ChEMBL project, and will be themed around the following areas.

  • Open-Source Drug Discovery and Open Science.
  • Patent data-mining and indexing.
  • Auto-curation and in-line predictive model generation.
  • An Ontology for drug discovery screening cascades.
  • A web-services primer.

    The mornings and evenings will be informal discussions of science, while the afternoons will be fun, fungi, flora and photography (who said alliteration is dead!) oriented walks in the wooded areas around Crieff. The picture above is of a reasonably rare parasite of truffles (a Cordyceps sp.) found in Crieff around the same time of year in 2008. This is the fruiting stage of the fungus (the teleomorph), the non-fruiting body stage (the anamorph) of a closely related fungus is the source of the powerful immunosuppresive drug cyclosporin, wow!

    I will try and get some really special VIP guests as surprise speakers and participants! ;)

  • Comments

    Popular posts from this blog

    ChEMBL 34 is out!

    We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site: Please see ChEMBL_34 release notes for full details of all changes in this release: New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

    New SureChEMBL announcement

    (Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

    Accessing SureChEMBL data in bulk

    It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the